Ovarian cancer is so deadly primarily because it is rarely caught early. More than half of all cases, 55%, have already spread to distant organs by the time they’re diagnosed. At that advanced stage, the five-year survival rate drops to just 32%. When caught early and still confined to the ovary, survival jumps to 92%, but only about 20% of women are diagnosed at that point. The gap between those two numbers explains most of the lethality.
Symptoms That Mimic Everyday Problems
The most common early symptoms of ovarian cancer are bloating, pelvic or abdominal pain, changes in bowel habits, loss of appetite, and feeling full quickly. About 39% of women in one large UK study reported abdominal pain, and another 39% reported bloating. These are symptoms most people would attribute to digestive issues, stress, or aging. Nothing about them screams “cancer,” which is exactly the problem.
The median time from when symptoms first appear to when a diagnosis is made is about 80 days. That’s nearly three months of a growing tumor while women and sometimes their doctors are reasonably attributing vague complaints to more common conditions like irritable bowel syndrome or urinary tract issues. By the time imaging or blood work finally happens, the cancer has often already spread beyond the ovary.
No Reliable Screening Test Exists
Unlike breast cancer (mammograms) or cervical cancer (Pap smears), there is no recommended screening test for ovarian cancer in average-risk women. The U.S. Preventive Services Task Force actively recommends against routine screening, giving it a grade D, meaning the harms outweigh the benefits. Every other major medical organization agrees: the American Cancer Society, the American College of Obstetricians and Gynecologists, and the American Academy of Family Physicians all say the same thing.
The two tools that exist, a blood test called CA-125 and transvaginal ultrasound, have real limitations when used for screening in healthy women. CA-125 can detect established cancers with reasonable accuracy (around 94% sensitivity at lower thresholds), but it also rises in many non-cancerous conditions like endometriosis, fibroids, and even menstruation. That creates a high rate of false positives, leading to unnecessary surgeries on women who don’t have cancer. And neither test has been shown to actually reduce deaths from ovarian cancer when used as a screening tool in the general population. So the disease essentially grows undetected until it causes problems significant enough to prompt investigation.
A Unique Way of Spreading
Most cancers spread through the bloodstream or lymph system. Ovarian cancer does too, but its primary route is different and particularly efficient. Cancer cells shed directly from the ovary’s surface into the peritoneal cavity, the open space surrounding the abdominal organs. They float in the fluid that naturally exists there, either as individual cells or as small clusters, and attach to the surfaces of nearby organs like the intestines, liver, and the omentum (a fatty tissue that drapes over the abdominal organs like an apron).
This process, called transcoelomic spread, means the cancer doesn’t need to break into blood vessels or lymph nodes to metastasize. It just drops into an environment that’s already designed to circulate fluid. As the disease progresses, large amounts of fluid called ascites accumulate in the abdomen. That fluid isn’t just a symptom; it’s a nutrient-rich environment packed with growth factors and immune cells that the cancer co-opts. The fluid actively supports the survival and growth of floating cancer cells, essentially giving them a place to thrive while they seed new tumors across the abdomen. Researchers have found that detached cancer cells undergo a metabolic shift, switching from sugar-based energy production to fat-based metabolism, which helps them survive and eventually colonize fatty tissue like the omentum.
Aggressive Biology From the Start
The most common and most lethal form of ovarian cancer, high-grade serous carcinoma, is biologically aggressive from its earliest stages. Virtually all of these tumors, around 97%, carry mutations in the TP53 gene, which normally acts as a critical brake on uncontrolled cell growth. When TP53 is knocked out, cells lose one of their most important safeguards against becoming cancerous. This mutation appears even in the earliest precursor lesions found in the fallopian tubes, suggesting the tumor is wired for aggressive behavior from the moment it begins forming.
Adding to the challenge, individual ovarian tumors contain a remarkable diversity of cell types. This internal variety, called intra-tumor heterogeneity, is one of the main reasons treatment eventually fails. A chemotherapy drug might kill 99% of the cells in a tumor, but the remaining 1% may carry traits that make them resistant. Those surviving cells repopulate the tumor, now composed almost entirely of treatment-resistant cells. Some of these resistant cell populations show characteristics associated with both aggressive growth and the ability to withstand standard chemotherapy drugs.
High Recurrence After Treatment
Even when initial treatment appears successful, ovarian cancer comes back at alarming rates. For women diagnosed at advanced stages, more than 80% will experience a recurrence after completing first-line treatment. Even early-stage disease recurs in roughly 25% of cases.
The timing of recurrence matters enormously. Women whose cancer returns more than six months after finishing chemotherapy are considered to have “platinum-sensitive” disease and can often be treated again with the same type of chemotherapy. But those whose cancer returns within six months are classified as “platinum-resistant,” meaning the cancer has adapted to the primary weapon used against it. A subset of patients are considered “platinum-refractory,” with disease that progresses during treatment or within a month of completing it. Each successive recurrence tends to be harder to treat and responds for shorter periods, creating a pattern of diminishing returns.
Why Early-Stage Detection Changes Everything
The survival data tells a stark story. When ovarian cancer is still localized to the ovary, the five-year survival rate is 92%. Once it spreads to nearby lymph nodes or tissues, that drops to 71%. Once it reaches distant sites, it falls to 32%. The biology of the cancer doesn’t change between these stages. What changes is how much of it there is and how many organs are involved, making complete surgical removal increasingly difficult and leaving more residual disease for chemotherapy to contend with.
The core tragedy of ovarian cancer is that it’s a survivable disease when found early, but almost everything about it conspires against early detection: symptoms that blend into everyday complaints, no effective screening test, a location deep in the pelvis where tumors can grow unnoticed, and a spreading mechanism that doesn’t require the cancer to breach any barriers. Until a reliable early detection method exists, the lethality of ovarian cancer will remain driven less by the limits of treatment and more by the fact that most women don’t know they have it until it’s widespread.